.jpg "Eiger Biopharmaceuticals (NASDAQ: EIGR)")
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Eiger Biopharmaceuticals (NASDAQ: EIGR), Miragen Therapeutics Inc (NASDAQ: MGEN) and Zealand Pharma A/S (NASDAQ: ZEAL) with bullish sentiments.
Eiger Biopharmaceuticals (NASDAQ: EIGR)
In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Eiger Biopharmaceuticals (NASDAQ: EIGR), with a price target of $26. The company’s shares opened today at $11.85.
Olson noted:
“EIGR expanded the license agreement for lonafarnib to include Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria), which is an ultra-orphan disease (incidence of 1 in 4 million live births). EIGR previously licensed rights to the development and potential use of lonafarnib in HDV. EIGR also started a collaboration with the Progeria Research Foundation (PRF), with ongoing clinical trials in Progeria. EIGR will supply lonafarnib and be responsible for a potential NDA filing for the Progeria indication based on PRF data. EIGR plans to seek FDA guidance regarding a potential regulatory approval for lonafarnib in Progeria. We view the expanded license as an opportunity for upside from this orphan indication in partnership with PRF, who will fund the trials.”
According to TipRanks.com, Olson is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -3.7% and a 42.3% success rate. Olson covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Conatus Pharmaceuticals, and Spero Therapeutics Inc.
Currently, the analyst consensus on Eiger Biopharmaceuticals is Strong Buy and the average price target is $25.75, representing an 117.3% upside.
In a report issued on May 9, B.Riley FBR also initiated coverage with a Buy rating on the stock with a $24 price target.
See today’s analyst top recommended stocks >>
Miragen Therapeutics Inc (NASDAQ: MGEN)
In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Miragen Therapeutics Inc (NASDAQ: MGEN), with a price target of $19. The company’s shares opened today at $7.51.
According to TipRanks.com, Moussatos is a 4-star analyst with an average return of 9.7% and a 44.2% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Catabasis Pharmaceuticals, and Global Blood Therapeutics.
Currently, the analyst consensus on Miragen Therapeutics Inc is Strong Buy and the average price target is $16.90, representing a 125.0% upside.
In a report issued on May 2, Oppenheimer also assigned a Buy rating to the stock with a $13 price target.
Zealand Pharma A/S (NASDAQ: ZEAL)
Needham analyst Alan Carr maintained a Buy rating on Zealand Pharma A/S (NASDAQ: ZEAL) today and set a price target of $26. The company’s shares opened today at $15.82.
Carr commented:
“Mgmt hosted a conference call today to provide a quarterly corporate update. Discussions w/ regulators in Europe and US around glepaglutide Short Bowel Syndrome (SBS) Phase 3 trial design have been completed and we believe initiation is most likely 3Q18 (was mid-2018). No changes in design from prior guidance and we expect top-line results in 2020 (unch). Phase 3 dasiglucagon severe hypoglycemia rescue trial still underway and we expect results 4Q18 (unch). We believe dasiglucagon Phase 3 trial initiation in Congenital Hyperinsulinism (CHI) is likely 3Q18 (was mid-2018). We believe glepaglutide opportunity in SBS is underappreciated, given Gattex launch trajectory at Shire and potential benefits over Gattex. Pathway to registration for dasiglucagon as a rescue pen and in CHI relatively short and straightforward.”
According to TipRanks.com, Carr is a 4-star analyst with an average return of 5.5% and a 42.2% success rate. Carr covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, ACADIA Pharmaceuticals Inc, and Rhythm Pharmaceuticals Inc.
Zealand Pharma A/S has an analyst consensus of Moderate Buy, with a price target consensus of $25.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
